We've found
184,457
clinical trials
Heart Failure Clinical Trial
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)
Status: Enrolling,
Phase
II
Updated: 2/28/2016
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)
Status: Enrolling,
Phase
II
Updated: 2/28/2016
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)
Status: Enrolling,
Phase
II
Updated: 2/28/2016
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Neurology, Orthopedics / Podiatry Clinical Trial
rTMS and Botulinum Toxin in Primary Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Muscle Invasive Bladder Cancer Clinical Trial
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Muscle Invasive Bladder Cancer Clinical Trial
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Cancer Clinical Trial
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Cancer Clinical Trial
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Cancer Clinical Trial
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Clinical Trial
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
We've found
184,457
clinical trials
Heart Failure Clinical Trial
Updated: 12/31/1969
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Updated: 12/31/1969
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Updated: 12/31/1969
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Updated: 12/31/1969
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Updated: 12/31/1969
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Updated: 12/31/1969
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Updated: 12/31/1969
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Heart Failure Clinical Trial
Updated: 12/31/1969
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Updated: 2/28/2016
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)
Status: Enrolling,
Phase
II
Updated: 2/28/2016
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Updated: 2/28/2016
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)
Status: Enrolling,
Phase
II
Updated: 2/28/2016
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Updated: 2/28/2016
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)
Status: Enrolling,
Phase
II
Updated: 2/28/2016
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Updated: 6/28/2016
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Updated: 6/28/2016
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Hepatitis C Clinical Trial
Updated: 6/28/2016
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Updated: 6/28/2016
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Updated: 6/28/2016
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Updated: 6/28/2016
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Updated: 6/28/2016
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Updated: 6/28/2016
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Colorectal Carcinoma Clinical Trial
Updated: 6/28/2016
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Status: Enrolling,
Phase
II
Updated: 6/28/2016
Click here to add this to my saved trials
Neurology, Orthopedics / Podiatry Clinical Trial
Updated: 12/31/1969
rTMS and Botulinum Toxin in Primary Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Muscle Invasive Bladder Cancer Clinical Trial
Updated: 12/31/1969
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Muscle Invasive Bladder Cancer Clinical Trial
Updated: 12/31/1969
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Cancer Clinical Trial
Updated: 12/31/1969
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Cancer Clinical Trial
Updated: 12/31/1969
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Cancer Clinical Trial
Updated: 12/31/1969
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 5/31/2017
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Enrolling,
Phase
III
Updated: 5/31/2017
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials